Migraine
Conditions
Brief summary
The purpose of this study is to investigate the safety and effectiveness of trigeminal nerve electrical stimulator on reducing the frequency of migraine onset. It is applied to migraine patients and analyzes the results by comparing them before and after 4weeks.
Detailed description
* Duration of study period (per participant): Screening period (-6\ 0weeks), Intervention period (4weeks). * Patient needs to visit site at least 3 times (Screening, Baseline, V4), V2 can be done with screening visit. V3 is tele-Visit. * The clinical trial device performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time. * During the study period, examination and treatment methods are carried out in the same way.
Interventions
DEVICEElexir (trigeminal nerve electrical stimulator)
Elexir performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
Sponsors
Nu Eyne Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women over 19 years old * Patients with migraine with or without migraine aura who meet ICHD-III (2018) diagnostic criteria 1.1 1.2 * Patients with history of migraine more than 1 year * Patients who have headaches at least twice a month * Those who do not take migraine prevention drugs from 12 weeks before screening to the end of the study, or who can maintain migraine prevention drugs during clinical trials without changing or adding additional migraine prevention drugs * A person who voluntarily agreed to participate in this clinical trial
Exclusion criteria
* Those who are diagnosed with primary headaches (exception: low-frequency intermittent tension type headaches) and secondary headaches in addition to migraine headaches * Those who are diagnosed with medication overuse headache in addition to migraine headaches * Pregnant or lactating of women within 6months * Among female subjects who are likely to be pregnant, those who disagree to contraception in a medically permitted manner during this clinical trial period. \*Medically permitted contraception: condom, Oral contraception that lasted for at least 3 months, contraceptive injection, contraceptive implant, intrauterine device, etc * Patients with mental illness who can interfere with their participation in the study. * In the case where medical devices for clinical trials cannot be applied due to being sensitive to orbital nerve stimulation. * Patients with a history of drug or alcohol abuse * Those who participated in other clinical trials within 30 days of screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the number of days of moderate to severe headache | baseline, 4 weeks | Check the number of days of moderate to severe headache at 4 weeks after start compared to baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in the number of headache days | baseline, 4 weeks | Check the number of headache days in 4 weeks after the start of stimulation compared to the baseline |
| Change in the frequency of headache days | baseline, 4 weeks | Check the frequency of headache days in 4 weeks after the start of stimulation compared to the baseline |
| Change in the frequency of taking the acute phase drug | baseline, 4 weeks | Check the frequency of taking the acute phase drug in 4 weeks after the start of stimulation compared to the baseline |
| Change in the headache effect assessment (HIT-6) score | baseline, 4 weeks | Check the change in the headache effect assessment (HIT-6) in 4 weeks after the start of stimulation compared to the baseline |
| Change in the migraine-related quality of life (MSQ 2.1) score | baseline, 4 weeks | Check the migraine-related quality of life (MSQ 2.1) change in 4 weeks after the start of stimulation compared to the baseline MSQ 2.1 measures the impact of migraine across three essential aspects. The MSQ total and scale score varies between 0 and 100 with higher scores indicating higher impact. |
| Change in pain intensity when headache occurs | baseline, 4 weeks | Check the change in pain intensity when headache occurs in 4 weeks after the start of stimulation compared to the baseline |
Countries
South Korea
Outcome results
None listed